In compliance with [89] Li et al., improved CD44/αvβ3 targeting ability was observed by [91] Shi and colleagues for HA and tetraiodothyroacetic acid (tetrac) carrying solid–liquid nanoparticles (TeHA-SLNs) compared to the monospecific match (HA or tetrac) in CD44 and αvβ3 overexpressing tumor cells and blood vessels of B16F10-melanoma-tumor-bearing C57BL/6 mice [91]. The gene discussed is CD44; the disease is neoplasm.